CTI BioPharma Corp. (GB:0RLB)

CTI BioPharma (0RLB) Share Price & Analysis


0RLB Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€0.65 - €0.65
Previous Close€0.65
Average Volume (3M)N/A
Market Cap
Enterprise Value€1.10B
Total Cash (Recent Filing)$59.01M
Total Debt (Recent Filing)$48.08M
Price to Earnings (P/E)-1.2
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding131,880,176
10 Day Avg. Volume217
30 Day Avg. VolumeN/A
Standard Deviation0.30
Financial Highlights & Ratios
Price to Book (P/B)-24.79
Price to Sales (P/S)15.24
Price to Cash Flow (P/CF)-9.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.50
Enterprise Value/Gross Profit21.78
Enterprise Value/Ebitda70.79
Price Target Upside1276.39% Upside
Rating ConsensusHold
Number of Analyst Covering8




What was CTI BioPharma Corp.’s price range in the past 12 months?
CTI BioPharma Corp. lowest share price was €0.65 and its highest was €0.65 in the past 12 months.
    What is CTI BioPharma Corp.’s market cap?
    Currently, no data Available
    When is CTI BioPharma Corp.’s upcoming earnings report date?
    CTI BioPharma Corp.’s upcoming earnings report date is Aug 03, 2023 which is in 53 days.
      How were CTI BioPharma Corp.’s earnings last quarter?
      CTI BioPharma Corp. released its earnings results on May 11, 2023. The company reported -€0.093 earnings per share for the quarter, beating the consensus estimate of -€0.106 by €0.013.
        Is CTI BioPharma Corp. overvalued?
        According to Wall Street analysts CTI BioPharma Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does CTI BioPharma Corp. pay dividends?
          CTI BioPharma Corp. does not currently pay dividends.
          What is CTI BioPharma Corp.’s EPS estimate?
          CTI BioPharma Corp.’s EPS estimate is -€0.07.
            How many shares outstanding does CTI BioPharma Corp. have?
            CTI BioPharma Corp. has 131,880,170 shares outstanding.
              What happened to CTI BioPharma Corp.’s price movement after its last earnings report?
              CTI BioPharma Corp. reported an EPS of -€0.093 in its last earnings report, beating expectations of -€0.106. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of CTI BioPharma Corp.?
                Among the largest hedge funds holding CTI BioPharma Corp.’s share is Perceptive Advisors LLC. It holds CTI BioPharma Corp.’s shares valued at N/A.


                  CTI BioPharma Stock Smart Score

                  The CTI BioPharma Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  CTI BioPharma Corp.

                  CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  CTI BioPharma
                  Cyclacel Pharmaceuticals
                  Karyopharm Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis